Translational Medicine
Clinical Pharmacology & Therapeutics (2007) 82, 595–600; doi:10.1038/sj.clpt.6100362; published online 26 September 2007
Advances in the Treatment of Tuberculosis
Y Zhang1
1Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA
Correspondence: Y Zhang, (yzhang@jhsph.edu)
Abstract
The current 6-month tuberculosis (TB) therapy is suboptimal with significant side effects and a poor patient compliance problem that frequently selects drug-resistant organisms. The increasing drug-resistant TB problem highlights the need to develop new and more effective drugs. Significant progress has been made recently with several new drug candidates currently in clinical trials. Improved understanding of persister biology and development of persister drugs are likely to be important for developing a more effective therapy.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Pyrazinamide ? on the antituberculosis drug frontlineNature Medicine News and Views (01 Jun 1996)
Shortening the treatment of tuberculosisNature Biotechnology News and Views (01 Feb 2005)
